 PRINCETON, N.J.--BUSINESS WIRE--UroGen Pharma Ltd. Nasdaq: URGN, a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial results for the first quarter ended March 31, 2021 and provided an overview of the Companys recent developments. We are pleased with the progress we have made across our expanded pipeline and the momentum weve seen since we reported fourth quarter 2020 earnings i 